Article

Novel mTORC1 inhibitors kill Glioblastoma stem cells

2020-06-19

Abstract excerpt

Glioblastoma Multiforme (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. mTORC1 regulates cell proliferation and has been shown by others to have reduced activity in GBMSC. We recently identified a novel chemical series of human-safe p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a5065c4e-e9dc-59e1-abbb-b0f72e1ab56f
DOI: 10.1101/2020.06.17.157735

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Novel mTORC1 inhibitors kill Glioblastoma stem cellsDOI 10.1101/2020.06.17.157735Read

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem CellsSemantic proximity Read

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivoSemantic proximity Read

Luteolin inhibits Musashi1 binding to RNA and disrupts cancer phenotypes in glioblastoma cells.Semantic proximity Read

Machine learning-driven discovery of potent isocitrate dehydrogenase 1 mutant inhibitors from ultralarge ligand libraries for targeting malignant glioma.Semantic proximity Read

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem CellsSemantic proximity Read

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating CellsSemantic proximity Read

The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodelingSemantic proximity Read

Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profileSemantic proximity Read

PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKTSemantic proximity Read

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.Semantic proximity Read

Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastomaSemantic proximity Read

Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trialsSemantic proximity Read